OOIR: Observatory of International Research

Papers

(The TQCC of Current Atherosclerosis Reports is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	124
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	82
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	75
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	72
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	67
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	64
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	57
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	54
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	51
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	51
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	51
Ambient Air Pollution and Atherosclerosis: Recent Updates	48
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	46
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	46
Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease (MINOCA): a Review of the Present and Preview of the Future	45
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	44
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	44
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	39
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	37
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	36
The Genetic Basis of Hypertriglyceridemia	36
The Emerging Specialty of Cardio-Rheumatology	34
RNA Silencing in the Management of Dyslipidemias	34
Percutaneous Coronary Interventions in Women	33
Inflammation in the Peri-ACS Period: Ready for Prime Time?	33

Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	32
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	30
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	30
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	30
mHealth Technology and CVD Risk Reduction	30
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	29
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease	28
The Role of Sleep in Cardiovascular Disease	28
Is There a Role of Coronary CTA in Primary Prevention? Current State and Future Directions	28
Lipoprotein(a): from Causality to Treatment	28
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	28
Hypertension in Women Across the Lifespan	28
Low LDL-C: Is It all Good News?	27
Transgender Cardiovascular Health: Practical Management for the Clinician	27
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	27
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	27
Update on Plant-Based Diets and Cardiometabolic Risk	26
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	26
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	24
Importance of Nutrition Security to CVD Prevention Efforts in the USA	24
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	24
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	23
COVID and Cardiovascular Disease: What We Know in 2021	23
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	23
Recent Advances in Stent Technology: Do They Reduce Cardiovascular Events?	22
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	22
Correction to: High-Density Lipoproteins and Serum Amyloid A (SAA)	22
Childhood Hypertriglyceridemia: Is It Time for a New Approach?	22
Sustainable Diets for Cardiovascular Disease Prevention and Management	21
Evidence Gaps in Assessments of the Healthiness of Online Supermarkets Highlight the Need for New Monitoring Tools: a Systematic Review	21
Dairy Foods: Is Its Cardiovascular Risk Profile Changing?	20
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	19
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	19
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	19
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	19
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	19
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know	18
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	18
Gene Regulatory Networks in Coronary Artery Disease	18
SR-B1’s Next Top Model: Structural Perspectives on the Functions of the HDL Receptor	18
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	18
Lipoprotein (a): Recent Updates on a Unique Lipoprotein	18
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	17
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	17
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	17
Wall Shear Stress Alteration: a Local Risk Factor of Atherosclerosis	17
Cardiovascular Health and Disease in the Pakistani American Population	17
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	16
What Causes Premature Coronary Artery Disease?	16
Bempedoic Acid: for Whom and When	16

Natural Sirtuin1 Activators and Atherosclerosis: an Overview	15
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	15
Utility of FFRCT in Patients with Chest Pain	15
Long-Term Cardiovascular Effects of COVID-19: Emerging Data Relevant to the Cardiovascular Clinician	15
Non-obstructive Plaque and Treatment of INOCA: More to Be Learned	15
Biology, Bias, or Both? The Contribution of Sex and Gender to the Disparity in Cardiovascular Outcomes Between Women and Men	15
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	15
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	14
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	14
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	14
Fixed Combination for the Treatment of Dyslipidaemia	14
Management of Hypercholesterolemia in Pregnant Women with Atherosclerotic Cardiovascular Disease	14
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins	14
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis	14
Apheresis: What Should a Clinician Know?	13
Diet, Food Insecurity, and CVD Risk in Sexual and Gender Minority Adults	13
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	13
LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?	13
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	13
Lipids: a Potential Molecular Pathway Towards Diastolic Dysfunction in Youth-Onset Type 2 Diabetes	13